Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis

ConclusionOverall, our analysis demonstrates a significant reporting signal for HBV reactivation with daratumumab and isatuximab.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research